
NVIDIA Partners with Eli Lilly, Thermo Fisher to Anchor AI Drug Discovery Infrastructure
NVIDIA is positioning itself as the central infrastructure provider for AI-driven pharmaceutical R&D through strategic partnerships with Eli Lilly and Thermo Fisher Scientific. The company's BioNeMo platform is being adopted by life sciences leaders as multiple biotech AI firms simultaneously launch foundation model platforms, signaling an industry-wide shift from traditional lab workflows to AI-native drug discovery processes.


















